DEVONSHIRE, BERMUDA--(Marketwired - July 08, 2013) - NeoMedigen Limited, a public company traded on the Bermuda Stock Exchange Main Board under Ticker Symbol NEOM:BH (BERMUDA: NEOM) announced today advancements in its bio-molecular technology and their relevance to obesity and aging skin. The Company has discovered that a single anti-aging enzyme SIRT-1 can be targeted directly through one of its external activators RezGen5. Normally, this enzyme is activated in the body by calorie restriction and exercise. The expectation is that NeoMedigen's small molecule will avert degenerative diseases of aging like diabetes, heart disease, immune function, corrective dermatology, and Alzheimer's.
The company's current focus is on the prevention of childhood obesity & aging skin. NeoMedigen's RezGen5 is designed to target childhood obesity which is one of the most serious public health challenges of the 21st century. Globally, in 2010 the number of overweight children under the age of five was estimated to be over 42 million. Close to 35 million of these are living in developing countries. Overweight and obese children are likely to stay obese into adulthood and more likely to develop non communicable diseases like diabetes and cardiovascular diseases at a younger age.
NeoMedigen's formulation for skin, NeoDerm/ND6 is specifically designed to avoid preventive dermatology with Botox, collagen shots, fillers, cosmetic surgery and other quick-fix solutions that come with health risks.
Stuart Garret, Co-Chairman and Founder of NeoMedigen, commented, "NeoMedigen is advancing a new class of therapeutics for diseases of aging. Our compounds are mimicking the benefits of a calorie restricted diet and exercise while lowering levels of glucose and insulin. It's a real game changer. These drugs in development would treat one disease, but unlike drugs of today, they would prevent 20 others. In effect, they would slow aging." Mr. Garret is co-inventor of RezGen5 with Dr. Ronald W. Pero who has had academic appointments at the Sloan Kettering Cancer Center/PMI Strang Clinic in New York City.
About NeoMedigen Limited
NeoMedigen Limited is a Bermuda based biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes, Alzheimer's and cardiovascular diseases. NeoMedigen is committed to improving the quality of human life by enabling people to do more, feel better and live longer. The company's headquarters are in Devonshire, Bermuda. For company information including a copy of this announcement and details of the company's updated product development pipeline, visit www.neomedigen.com.